CLINICAL TRIALS PROFILE FOR CVL-231
✉ Email this page to a colleague
Clinical Trials for CVL-231
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04136873 ↗ | A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia | Completed | Cerevel Therapeutics, LLC | Phase 1 | The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-231 following multiple-dose oral administration in subjects with schizophrenia. |
| NCT04787302 ↗ | PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing | Recruiting | Cerevel Therapeutics, LLC | Phase 1 | PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing |
| NCT05106309 ↗ | Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants | Not yet recruiting | Cerevel Therapeutics, LLC | Phase 1 | A 2-part, crossover design, open-label treatment trial with 4 periods, 4 sequences (Part A) to evaluate MR formulations of CVL-231 and a 2 periods, 2 sequences (Part B) to understand effect of food on CVL-231 exposures from an MR formulation. |
| NCT05227690 ↗ | A Placebo-controlled Trial of 10 and 30 mg QD Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis | Not yet recruiting | Cerevel Therapeutics, LLC | Phase 2 | This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis. |
| NCT05227703 ↗ | A Placebo-controlled Trial of 15 and 30 mg QD Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis | Not yet recruiting | Cerevel Therapeutics, LLC | Phase 2 | This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis. |
| NCT05245539 ↗ | Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia | Recruiting | Cerevel Therapeutics, LLC | Phase 1 | The purpose of this trial is to characterize the effects of 2 oral doses (over 8 weeks total) of CVL-231 on ambulatory blood pressure and heart rate in patients with stable schizophrenia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for CVL-231
Condition Name
Clinical Trial Locations for CVL-231
Trials by Country
Clinical Trial Progress for CVL-231
Clinical Trial Phase
Clinical Trial Sponsors for CVL-231
Sponsor Name
